drugset / Trial / NCT05698888
Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.
Timeline
- Start
- 2022-11-29
- Primary completion
- 2023-06-19
- Completion
- 2023-06-19
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VP301 | Unknown | — | Intravenous |